Katrin Rupalla, Ph.D., is the Chair of the Board and has served as our director since April 2021. Dr. Rupalla has more than 25 years’ experience in the pharmaceutical industry at a global scale serving the United States, Europe and China. Currently, Dr. Rupalla serves as CEO of Ymmunobio AG, a Swiss preclinical stage biotech company since December 2021. Prior to this she was the Senior Vice President of Regulatory Affairs, R&D Quality and Medical Information at Lundbeck between October 2019 and November 2021. She held several leadership roles at Bristol Myers Squibb in drug development and regulatory affairs including as Head Development BMS in China, Vice President of European Union Regulatory Sciences, and Vice President of Oncology Global Regulatory Sciences. Dr. Rupalla has spent her career as an executive in global regulatory affairs at various other companies including Celgene, Roche, and Merck. Presently, she is a also non-executive independent director at 4D Pharma PLC.
Dr. Rupalla received a Master of Science in Pharmacy and a Ph.D. in CNS pharmacology from Philipps University of Marburg, Germany. She also has an MBA from Jones International University, CO, USA and has a NED Diploma from Financial Times.